Haste Plus Speed: The Need to Ensure COVID-19 Vaccines Don't Make Infections Worse

By Sandi Wong, Assistant Editor



Biopharmaceutical Report II


Issue21_April 2020




"THERE IS A HUGH DIFFERENCE BETWEEN THE POSSIBILITY THAT A VACCINE WILL SENSITIZE A SUSCEPTIBLE, SERONEGATIVE RECIPIENT TO AN ANTIBODY-ENHANCED DISEASE AND THE REALITY THAT IT ACTUALLY DOES."
SCOTT HALSTEAD, USUHS

The rush to make a vaccine for COVID-19 has raised concern that some candidate treatments could make infections worse. The main risk is the chance of inducing antibody-dependent enhancement, a process known to complicate vaccine development in Dengue and several other diseases.


The topic drew attention at a global online forum sponsored last month by WuXi Apptec Co. Ltd. (Shanghai:603259; HKEX:2359) (see “Plotting a Scientific Path to Counter COVID-19”). ADE is usually triggered by non-neutralizing antibodies or sub-neutralizing levels of antibodies. Two papers published in Cell and the Journal of Virology in February showed it can happen with neutralizing antibodies as well.

While it’s too early to know if COVID-19 carries a risk of ADE, other coronaviruses, including SARS-CoV and MERS-CoV, have been associated with the phenomenon, Scott Halstead, who introduced the ADE concept 40 years ago, told BioCentury.


This does not make ADE a foregone conclusion with COVID-19, Halstead noted. “There is a huge difference between the possibility that a vaccine will sensitize a susceptible (seronegative) recipient to an antibody-enhanced disease and the reality that it actually does.” Halstead is an adjunct professor at the Uniformed Services University of the Health Sciences.

For SARS and MERS, antibodies against the viruses -- elicited either by infection or vaccination -- have been shown to cause ADE in animal models, including non-human primates. In cell cultures, they have been shown to potentiate infection of primary human macrophages.


There’s also evidence that feline infectious peritonitis virus, a coronavirus that infects domestic cats, is enhanced both by maternal antibodies transferred to kittens and by vaccination, resulting in severe and fatal feline disease.


Halstead is unaware of any “evidence that severe or fatal SARS or MERS result from antibody-mediated infections.”


Vaccine developers “must be aware of and look for” the possibility of ADE caused by COVID-19 vaccines, he cautioned.

In Dengue, the phenomenon has held up vaccine development for several drug developers (see “Dengvaxia’s Warning”).

Johan Van Hoof, global therapeutic area head for infectious diseases and vaccines at Janssen unit of Johnson & Johnson (NYSE:JNJ), told BioCentury that ADE is linked to an imbalance of responses of two types of T cell, Th2 vs Th1, favoring the former.


Van Hoof thinks companies could use this fact during Phase I testing to demonstrate a low risk of ADE by showing their candidate induces a Th1-driven immune profile. Showing a vaccine candidate elicits neutralizing antibodies will also be important, he said.




Designing out ADE


A variety of vaccine design approaches have been proposed to help lower risk for ADE.

Most companies developing COVID-19 vaccines have not said whether they are using these or other approaches.

Kizzmekia Corbett, scientific lead of the coronavirus team at NIH’s vaccine research center, previously told BioCentury that the candidate from Moderna Inc. (NASDAQ:MRNA), mRNA-1273, which encodes the virus’ spike protein, incorporates mutations that stabilize the spike in a prefusion conformation to ensure it induces the right kind of antibodies to confer protection.

Peter Hotez, co-director of Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, told BioCentury his team’s strategy involves “reducing the size of the subunit vaccine” to focus the immune response on the receptor-binding domain of the spike protein.

CureVac AG spokesperson Thorsten Schüller told BioCentury the company took into account preclinical and animal data regarding coronavirus-associated ADE “for the design of our vaccine candidates for SARS-CoV-2 by carefully selecting the target protein.” He declined to disclose the details.

Janssen spokesperson Paul Graves told BioCentury the company is exploring approaches that “target all or some parts of the protein” for its vaccine and “will select which targets to pursue based on the results of our early research.”

Moderna’s mRNA-1273, partnered with NIH, will be among the first preventative vaccines to enter the clinic; it is scheduled to start Phase I testing Friday. The first clinical batch of mRNA-1273 was delivered 42 days after the genome of the virus that causes COVID-19 was released; design and manufacturing took 25 days.

CureVac hopes to have an mRNA vaccine in the clinic by June or July, and Janssen plans to take a candidate from its recombinant adenovirus (rAdV) vector platform into the clinic within a year.

More than three dozen companies and academic groups have announced COVID-19 vaccine programs (see “A Growing List of Vaccines” and “U.S. Testing of Coronavirus Vaccine, Therapeutic Begin”).



EDITORIAL & RESEARCH


NEWSROOM: pressreleases@biocentury.com SAN CARLOS, CA: +1 650-595-5333 CHICAGO: +1 312-755-0798 WASHINGTON, DC: +1 202-462-9582 UNITED KINGDOM: +44 (0)1865-512184

BioCentury Innovations: Idea to IND BioCentury: Phase I to the Patient BioCentury Extra: Essential News for Biotech and Pharma

C. Simone Fishburn, Ph.D., Editor in Chief Editors Emeritus: Susan Schaeffer (2012-2018); Karen Bernstein, Ph.D. (1992-2012)

Jeff Cranmer, Selina Koch, Ph.D., Executive Editors

Steve Usdin, Senior Editor/Washington & Head: Policy & Regulation

Lauren Martz, Senior Editor, Head of Translation & Clinical Development

Karen Tkach Tuzman, Ph.D., Associate Editor & Head: Discovery and Preclinical Development

Paul Bonanos, Stephen Hansen, Virginia Li, Inhua Muijrers-Chen, Ph.D., Karen Tkach Tuzman, Ph.D., Associate Editors Meredith Durkin Wolfe, Winnie Pong, Ph.D., Associate Editors, Data & Analytics Sandi Wong, Ph.D., Assistant Editor Allison Johnson, Ph.D., Senior Writer Elizabeth S. Eaton, Hongjiang Li, Ph.D., Claire Quang, Staff Writers


USE OF IMAGES: Certain Images used in BioCentury Inc.’s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see “Use of Images” found under the “Legal”section on the footer of the homepage at www.biocentury.com.BioCentury®; Because Real Intelligence is Hard to FindTM; BCIQTM; The BioCentury 100TM; and The Clear Route to ROITM are trademarks of BIOCENTURY INC. All contents Copyright © 2020, BIOCENTURY INC. ALL RIGHTS RESERVED. No part of BioCentury’s Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited in any form or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury’s Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury’s Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein or for any decision made or action taken in reliance upon such information. All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc.

CORPORATE, SUBSCRIPTIONS & PRIVACY


BioCentury’s mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury Inc. BioCentury International Inc.


MAIN OFFICES 1235 Radio Road, Ste. 100 Redwood City, CA 94065-1217 +1 650-595-5333; Fax: +1 650-595-5589

CORPORATE Karen Bernstein, Ph.D., Co-Founder & Chairman David Flores, Co-Founder, President & CEO C. Simone Fishburn, Ph.D., Vice President/Editor in Chief Adam Gordon: Vice President/ Product Management & Marketing David Smiling: Chief Technology Officer Bennet Weintraub: Vice President/ Administration & CFO Eric Pierce: Publisher Susan Morgan: Senior Director/Administration & Human Resources


BUSINESS DEVELOPMENT Joshua Berlin, Executive Director Juli Balestrieri, Kevin Lehnbeuter, Business Development Managers

PRODUCT MANAGEMENT & MARKETING Greg Monteforte, Director/Marketing & Promotional Services Josephine Asciutto-Bunn, Marketing Coordinator

SUBSCRIBER SERVICES Tim Tulloch, Senior Director Orlando Abello, Matt Krebs, Michelle Ortega, Ron Rabinowitz, Account Managers Hannibal Adofo, Marilyn Smith, Subscriber Services

TECHNOLOGY Jenny Nichols, Director/Publishing Lam Lu, Head/Business Intelligence Group


BUSINESS SERVICES Accounting & Billing: finance@biocentury.com Conferences: conferences@biocentury.com Data Solutions Support: support@biocentury.com Privacy Policy: privacy@biocentury.com Reprints/Permissions: businessservices@biocentury.com

PRIVACY & ADVERTISING In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties. BioCentury does NOT sell advertising in the BioCentury, BioCentury Innovations or BioCentury Week in Review publications. BioCentury is pleased to acknowledge its conference partners and sponsors through promotional announcements in its publications. BioCentury MAY accept paid promotional messages from sponsors, which are displayed only on BioCentury’s websites and in BioCentury Extra.




This edition and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon

Subscribe to Our Journal

Email: wgroup@wmedical.org
Tel: 201-402-1400